Aker BioMarine ASA
10.82
EUR
-0.14
(-1.28%)
ISIN
NO0010886625
Return %
Stock
S&P 500
1Y
35.25
14.20
3Y
208.70
81.12
5Y
132.94
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Matts Eirik Johansen
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- Lysaker Norway
- IPO Date
- Jul 6, 2020
- Website
- akerbiomarine.com
- Similar Companies
- Business
- Aker BioMarine ASA is a biotechnology and marine ingredients company that specializes in the development, harvesting, processing, and commercialization of Antarctic krill-derived products for human health, functional nutrition, and wellness. Founded in 2006 and headquartered in Lysaker, Norway, the company operates as a subsidiary of Aker ASA and serves dietary supplement brands, pharmaceutical developers, and consumer retail channels worldwide. The company manages its operations across three core business segments: Human Health Ingredients, Consumer Health Products, and Emerging Businesses. The company's product and service portfolio encompasses bulk nutritional raw materials, advanced delivery technologies, private-label manufacturing, and branded consumer health formulations. In its Human Health Ingredients division, the company offers Superba Krill and Superba Boost krill oil extracts, which deliver omega-3 fatty acids, phospholipids, and choline for cardiovascular, cellular, and joint health; Lysoveta, an enzymatically concentrated lysophosphatidylcholine platform designed for targeted brain, eye, and metabolic health applications; PL+, a specialized phospholipid delivery matrix engineered to enhance nutrient bioavailability; and Revervia, a marine-derived natural astaxanthin antioxidant. Through its Consumer Health Products division, operated via subsidiaries including Epion Brands Inc. and Lang Pharma Nutrition Inc., the company manufactures customized, private-label dietary supplements for global retail chains and markets branded nutritional supplements under the Kori Krill Oil label. In its Emerging Businesses segment, the company develops bio-based and circular applications, including Understory bioavailable marine proteins; KRBNX organic biostimulants and agricultural crop nutrition; CaPre, a pharmaceutical-grade phospholipid therapy candidate for cardiometabolic disorders; AION circular plastic waste reduction solutions; and Qpaws, a digital pet wellness platform. Aker BioMarine conducts business across Europe, the Americas, and the Asia-Pacific region, supported by advanced manufacturing, science, and extraction operations located in Houston, Texas, alongside global supply chain hubs and regional offices in Spain and the United States. In recent corporate developments, Aker BioMarine completed the divestment of its Feed Ingredients business unit, encompassing the QRILL Aqua and QRILL Pet product lines, in September 2024 to Aker QRILL Company—a joint venture entity owned 60% by American Industrial Partners and 40% by Aker Capital—at an enterprise value of USD 590 million, solidifying the company's strategic pivot toward high-value human health and precision nutrition. Following the divestment, the company executed a comprehensive operational restructuring through 2024 and 2025, centralizing research, technology development, procurement, and quality assurance functions at its Houston facility while transitioning logistics and customer care management to Spain. In 2026, Aker BioMarine underwent a strategic corporate reorganization and statutory merger with its majority shareholder, Aker ASA, transitioning the business into a private ownership structure to accelerate long-term growth across its core biotechnology and human health portfolio.